Original GlobalRPh source
- Product / population
- Preserved GlobalRPh source, not a freshly verified product label
- Renal measure
- Use the method specified in the original source
Historical source: not automatically current. Review current official labeling and separately attributed additions before use.
Usual Dosing (Adults)
Give loading doses undiluted as supplied. Maintenance infusions may use normal or half-normal saline at 1 to 3 mg/mL; use diluted solutions within 24 hours. May administer through a Y-connector into a running dextrose infusion or directly into tubing.
Do not dilute directly in dextrose: a chemical interaction develops over 24 hours. Do not give furosemide in a line containing inamrinone: immediate precipitation occurs.
Start 0.75 mg/kg over 2 to 3 minutes, then maintenance 5 to 10 micrograms/kg/min. An additional 0.75 mg/kg loading dose may be given 30 minutes after initiation based on response. Usual total including loads should not exceed 10 mg/kg/day; limited studies support up to 18 mg/kg/day for shortened durations.
Loading-dose chart (undiluted):
| Weight (kg) | 30 | 40 | 50 | 60 | 70 | 80 | 90 | 100 | 110 | 120 |
|---|---|---|---|---|---|---|---|---|---|---|
| Volume (mL) | 4.5 | 6 | 7.5 | 9 | 10.5 | 12 | 13.5 | 15 | 16.5 | 18 |
The infusion chart requires 2.5 mg/mL (2500 micrograms/mL), prepared by equal volumes of inamrinone solution and saline. Example: three 20 mL vials (60 mL) plus 60 mL saline = 120 mL at 2.5 mg/mL.
| Dose/weight | 30 kg | 40 kg | 50 kg | 60 kg | 70 kg | 80 kg | 90 kg | 100 kg | 110 kg | 120 kg |
|---|---|---|---|---|---|---|---|---|---|---|
| 5 micrograms/kg/min, mL/hour | 4 | 5 | 6 | 7 | 8 | 10 | 11 | 12 | 13 | 14 |
| 7.5 micrograms/kg/min, mL/hour | 5 | 7 | 9 | 11 | 13 | 14 | 16 | 18 | 20 | 22 |
| 10 micrograms/kg/min, mL/hour | 7 | 10 | 12 | 14 | 17 | 19 | 22 | 24 | 26 | 29 |
The source example: 70 kg requires 10.5 mL undiluted loading dose; at 7.5 micrograms/kg/min, use 13 mL/hour of 2.5 mg/mL. These are rounded source chart values.
Adjust rate/duration to response and adverse effects, reducing/titrating down as necessary. Expected concentration is approximately 3 micrograms/mL; cardiac-index increases are linearly related over 0.5 to 7 micrograms/mL, without observations above that range.
Improvement may include increased cardiac output, reduced wedge pressure, and less dyspnea, orthopnea and fatigue. CVP monitoring may help assess hypotension/fluid balance. Correct or adjust fluids/electrolytes beforehand. Do not use particulate or discolored products.
Renal Dosing
CrCl >10 mL/min: no change. CrCl <10: administer 50% to 75% of dose.
Hemodialysis
Specific guidelines not available. Refer to CrCl <10 dosing.